The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction

Jerrod N. Keith, Tae W. Chong, Diwakar Davar, Alexander G. Moore, Alison Morris, Michael L. Gimbel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients. Methods: Patients undergoing breast reconstruction performed by a single surgeon over a 5-year period were evaluated retrospectively. The authors introduced preoperative chemoprophylaxis with enoxaparin in all breast reconstructions during this time. Prosthetic-based and microsurgical breast reconstructions were examined. Patients were divided into two groups: those who did and those who did not receive preoperative enoxaparin. The authors reviewed patient demographics, comorbidities, and complications, focusing on bleeding complications. Results: Three hundred patients (450 breasts) were included. One hundred fifty-four patients (244 breasts) underwent reconstruction with tissue expanders, and 146 (206 breasts) underwent free flap reconstructions. One hundred seventy-nine of 300 were given preoperative enoxaparin. Eleven hematomas occurred, eight (4.5 percent) in the enoxaparin group and three (2.5 percent) without enoxaparin (p = 0.399). Blood transfusions were given to four patients (2.2 percent) who received enoxaparin and one patient (0.8 percent) who did not (p = 0.652). Finally, any type of bleeding complication occurred in 11 patients (6.1 percent) with enoxaparin and in four (3.3 percent) without (p = 0.419). Larger breasts were more likely to receive enoxaparin (p = 0.011), which did not result in higher bleeding complications. Conclusion: In this retrospective study, the authors found that preoperative chemoprophylaxis in breast reconstruction was associated with an acceptable rate of postoperative bleeding complications. Clinical Question/Level of Evidence: Therapeutic, III.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalPlastic and Reconstructive Surgery
Volume132
Issue number2
DOIs
StatePublished - Aug 2013

Fingerprint

Enoxaparin
Mammaplasty
Low Molecular Weight Heparin
Chemoprevention
Hemorrhage
Breast
Venous Thromboembolism
Tissue Expansion Devices
Free Tissue Flaps
Blood Transfusion
Hematoma
Comorbidity
Retrospective Studies
Demography

ASJC Scopus subject areas

  • Surgery

Cite this

The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction. / Keith, Jerrod N.; Chong, Tae W.; Davar, Diwakar; Moore, Alexander G.; Morris, Alison; Gimbel, Michael L.

In: Plastic and Reconstructive Surgery, Vol. 132, No. 2, 08.2013, p. 279-284.

Research output: Contribution to journalArticle

Keith, Jerrod N. ; Chong, Tae W. ; Davar, Diwakar ; Moore, Alexander G. ; Morris, Alison ; Gimbel, Michael L. / The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction. In: Plastic and Reconstructive Surgery. 2013 ; Vol. 132, No. 2. pp. 279-284.
@article{e20e889597244f7e8ff61100c93d2d5b,
title = "The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction",
abstract = "Background: Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients. Methods: Patients undergoing breast reconstruction performed by a single surgeon over a 5-year period were evaluated retrospectively. The authors introduced preoperative chemoprophylaxis with enoxaparin in all breast reconstructions during this time. Prosthetic-based and microsurgical breast reconstructions were examined. Patients were divided into two groups: those who did and those who did not receive preoperative enoxaparin. The authors reviewed patient demographics, comorbidities, and complications, focusing on bleeding complications. Results: Three hundred patients (450 breasts) were included. One hundred fifty-four patients (244 breasts) underwent reconstruction with tissue expanders, and 146 (206 breasts) underwent free flap reconstructions. One hundred seventy-nine of 300 were given preoperative enoxaparin. Eleven hematomas occurred, eight (4.5 percent) in the enoxaparin group and three (2.5 percent) without enoxaparin (p = 0.399). Blood transfusions were given to four patients (2.2 percent) who received enoxaparin and one patient (0.8 percent) who did not (p = 0.652). Finally, any type of bleeding complication occurred in 11 patients (6.1 percent) with enoxaparin and in four (3.3 percent) without (p = 0.419). Larger breasts were more likely to receive enoxaparin (p = 0.011), which did not result in higher bleeding complications. Conclusion: In this retrospective study, the authors found that preoperative chemoprophylaxis in breast reconstruction was associated with an acceptable rate of postoperative bleeding complications. Clinical Question/Level of Evidence: Therapeutic, III.",
author = "Keith, {Jerrod N.} and Chong, {Tae W.} and Diwakar Davar and Moore, {Alexander G.} and Alison Morris and Gimbel, {Michael L.}",
year = "2013",
month = "8",
doi = "10.1097/PRS.0b013e318295870e",
language = "English (US)",
volume = "132",
pages = "279--284",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction

AU - Keith, Jerrod N.

AU - Chong, Tae W.

AU - Davar, Diwakar

AU - Moore, Alexander G.

AU - Morris, Alison

AU - Gimbel, Michael L.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients. Methods: Patients undergoing breast reconstruction performed by a single surgeon over a 5-year period were evaluated retrospectively. The authors introduced preoperative chemoprophylaxis with enoxaparin in all breast reconstructions during this time. Prosthetic-based and microsurgical breast reconstructions were examined. Patients were divided into two groups: those who did and those who did not receive preoperative enoxaparin. The authors reviewed patient demographics, comorbidities, and complications, focusing on bleeding complications. Results: Three hundred patients (450 breasts) were included. One hundred fifty-four patients (244 breasts) underwent reconstruction with tissue expanders, and 146 (206 breasts) underwent free flap reconstructions. One hundred seventy-nine of 300 were given preoperative enoxaparin. Eleven hematomas occurred, eight (4.5 percent) in the enoxaparin group and three (2.5 percent) without enoxaparin (p = 0.399). Blood transfusions were given to four patients (2.2 percent) who received enoxaparin and one patient (0.8 percent) who did not (p = 0.652). Finally, any type of bleeding complication occurred in 11 patients (6.1 percent) with enoxaparin and in four (3.3 percent) without (p = 0.419). Larger breasts were more likely to receive enoxaparin (p = 0.011), which did not result in higher bleeding complications. Conclusion: In this retrospective study, the authors found that preoperative chemoprophylaxis in breast reconstruction was associated with an acceptable rate of postoperative bleeding complications. Clinical Question/Level of Evidence: Therapeutic, III.

AB - Background: Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients. Methods: Patients undergoing breast reconstruction performed by a single surgeon over a 5-year period were evaluated retrospectively. The authors introduced preoperative chemoprophylaxis with enoxaparin in all breast reconstructions during this time. Prosthetic-based and microsurgical breast reconstructions were examined. Patients were divided into two groups: those who did and those who did not receive preoperative enoxaparin. The authors reviewed patient demographics, comorbidities, and complications, focusing on bleeding complications. Results: Three hundred patients (450 breasts) were included. One hundred fifty-four patients (244 breasts) underwent reconstruction with tissue expanders, and 146 (206 breasts) underwent free flap reconstructions. One hundred seventy-nine of 300 were given preoperative enoxaparin. Eleven hematomas occurred, eight (4.5 percent) in the enoxaparin group and three (2.5 percent) without enoxaparin (p = 0.399). Blood transfusions were given to four patients (2.2 percent) who received enoxaparin and one patient (0.8 percent) who did not (p = 0.652). Finally, any type of bleeding complication occurred in 11 patients (6.1 percent) with enoxaparin and in four (3.3 percent) without (p = 0.419). Larger breasts were more likely to receive enoxaparin (p = 0.011), which did not result in higher bleeding complications. Conclusion: In this retrospective study, the authors found that preoperative chemoprophylaxis in breast reconstruction was associated with an acceptable rate of postoperative bleeding complications. Clinical Question/Level of Evidence: Therapeutic, III.

UR - http://www.scopus.com/inward/record.url?scp=84881441990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881441990&partnerID=8YFLogxK

U2 - 10.1097/PRS.0b013e318295870e

DO - 10.1097/PRS.0b013e318295870e

M3 - Article

C2 - 23897327

AN - SCOPUS:84881441990

VL - 132

SP - 279

EP - 284

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 2

ER -